Valuation: Incyte Corporation

Market Cap 23.32B 20.43B 18.84B 17.4B 33B 2,224B 33.55B 225B 88.26B 1,095B 87.54B 85.64B 3,770B P/E 2026 *
37.9x
P/E 2027 * 17.3x
Enterprise Value 18.3B 16.03B 14.78B 13.66B 25.9B 1,745B 26.33B 177B 69.26B 860B 68.7B 67.2B 2,958B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 2.68x
Free-Float
98.1%
Yield 2026 *
-
Yield 2027 * -
1 day-1.53%
1 week-0.13%
Current month+2.96%
1 month+10.74%
3 months+21.48%
6 months+9.21%
Current year+18.16%
1 week 114.27
Extreme 114.27
118.97
1 month 96.09
Extreme 96.09
118.97
Current year 89.25
Extreme 89.25
118.97
1 year 67.17
Extreme 67.17
118.97
3 years 50.27
Extreme 50.27
118.97
5 years 50.27
Extreme 50.27
118.97
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 2025-06-25
Director of Finance/CFO 57 2026-05-03
President 62 2023-06-04
Director TitleAgeSince
Chairman 59 2025-06-25
Director/Board Member 72 2015-01-19
Director/Board Member 64 2015-01-19
Date Insider Type Main position Quantity % Market Cap.
07-01Tax

Chief Technology Officer

-2,177 0.0011%
07-01Tax

Principal Accounting Officer

-477 0.0002%
07-01Tax

EVP & Chief Scientific Officer

-350 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%-0.13%+65.92%+88.58% 23.32B
-0.51%+1.57%+18.72%-5.52% 67.61B
-5.16%-8.63%+37.37%+202.27% 51.6B
+5.28%+39.50%+39.50%+39.50% 43B
-2.10%+0.89%-49.30%-53.47% 40.94B
+0.12%-7.85%+47.16%-29.27% 29.4B
-10.83%-14.41%+99.15%-44.54% 27.09B
+3.88%+2.16%+11.78%+201.51% 19.89B
-1.59%-1.63%+61.04%+130.75% 16.91B
-4.75%+11.27%+85.63%+394.76% 16.84B
Average -1.72%-1.59%+41.70%+92.46% 33.66B
Weighted average by Cap. -1.53%-2.13%+33.25%+66.66%

Financials

2026 *2027 *
Net sales 5.63B 4.93B 4.55B 4.2B 7.96B 537B 8.1B 54.3B 21.3B 264B 21.12B 20.67B 910B 6.14B 5.38B 4.96B 4.58B 8.68B 585B 8.83B 59.2B 23.22B 288B 23.03B 22.53B 992B
Net income 637M 558M 514M 475M 901M 60.73B 916M 6.15B 2.41B 29.92B 2.39B 2.34B 103B 1.4B 1.23B 1.13B 1.05B 1.99B 134B 2.02B 13.55B 5.32B 65.97B 5.27B 5.16B 227B
Net Debt -5.02B -4.4B -4.05B -3.75B -7.1B -479B -7.22B -48.43B -19B -236B -18.84B -18.43B -811B -6.87B -6.02B -5.55B -5.13B -9.73B -656B -9.89B -66.33B -26.02B -323B -25.81B -25.25B -1,111B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
26-07-10 US$116.71 -1.53% 1,643,980
26-07-09 US$118.52 +1.07% 1,353,569
26-07-08 US$117.26 -0.67% 1,878,406
26-07-07 US$118.05 +2.10% 1,667,760
26-07-06 US$115.62 -1.06% 1,277,144
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
116.71USD
Average target price
111.45USD
Spread / Average Target
-4.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock